Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review.
Edgaras SmolskasGoda MikulskytėErnestas SileikaKestutis SuziedelisAudrius DulskasPublished in: International journal of molecular sciences (2022)
According to current guidelines, the current treatment for locally advanced rectal cancer is neoadjuvant therapy, followed by a total mesorectal excision. However, radiosensitivity tends to differ among patients due to tumor heterogeneity, making it difficult to predict the possible outcomes of the neoadjuvant therapy. This review aims to investigate different types of tissue-based biomarkers and their capability of predicting tumor response to neoadjuvant therapy in patients with locally advanced rectal cancer. We identified 169 abstracts in NCBI PubMed, selected 48 reports considered to meet inclusion criteria and performed this systematic review. Multiple classes of molecular biomarkers, such as proteins, DNA, micro-RNA or tumor immune microenvironment, were studied as potential predictors for rectal cancer response; nonetheless, no literature to date has provided enough sufficient evidence for any of them to be introduced into clinical practice.
Keyphrases
- rectal cancer
- locally advanced
- systematic review
- neoadjuvant chemotherapy
- phase ii study
- clinical practice
- meta analyses
- squamous cell carcinoma
- stem cells
- randomized controlled trial
- early stage
- clinical trial
- adipose tissue
- metabolic syndrome
- insulin resistance
- open label
- mesenchymal stem cells
- cell therapy
- skeletal muscle